Prioritisation List (EPL) – Pharmaceuticals

EUnetHTA prioritises topics for Joint Assessments

EUnetHTA has published the second iteration of the EUnetHTA Prioritisation List (EPL). The EPL expresses the identified significant interest of national HTA bodies in relation to individual compounds as presented in the list. By proactively selecting those topics in direct collaboration with national bodies, EUnetHTA strives to increase the implementation of Joint Assessments at the national level. This is one of the key elements of Joint Action 3.

The EPL is published as part of the overarching Topic Identification, Selection and Prioritisation (TISP) task group. The topics identified and prioritised in the first EPL remain relevant and valid.

Topics have been identified through horizon scanning activities and via feedback from EMA and EUnetHTA partners. Selection and prioritisation are based on four criteria:

• Whether the topic is of national/sub/national interest;
• Uptake;
• Whether the partners are interested in being part of the authoring team for a specific compound;
• Feasibility in relation to timelines.

Attaining the EPL listing demonstrates a significant degree of interest on the part of HTA bodies in receiving a Joint Relative Efficacy Assessment (REA) on the specific topic. EUnetHTA will, therefore, engage with all companies on the EPL in order to establish further dialogue to increase the opportunities for collaboration on prioritised topics.

* EUnetHTA JA3 will not be accepting any further Letters of Intent with regard to new pharma Joint Assessments through the end of Joint Action 3 on 31st May, 2021.
For further information please contact:

wp4_pharmaceuticals@zinl.nl